Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor,for NF2 Patients with Progressive or Symptomatic Meningiomas

Abstract

Meningiomas are common in neurofibromatosis 2 (NF2) patients with a cumulative incidence of80 by 70 years of age. Meningiomas that progress despite surgery and radiation are an important unmet medical need for these patients. To date, no chemotherapy has demonstrated efficacy against NF2-related meningiomas. Our laboratory studies have shown that treatment of primary meningioma cells with AZD2014, a mTORC1/mTORC2 inhibitor, leads to decreased cell viability/proliferation. Thus, we hypothesize that AZD2014 will be effective in treating symptomatic or progressive meningiomas in NF2 patients.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jun 01, 2017
Accession Number
AD1045677

Entities

People

  • Scott R. Plotkin

Organizations

  • Massachusetts General Hospital

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Buildings And Structures
  • Chemotherapy
  • Clinical Trials
  • Computational Biology
  • Data Analysis
  • Department Of Defense
  • Disease Attributes
  • Inhibitors
  • Neoplasms
  • Nervous System Diseases
  • Neurofibromatosis
  • Radiation
  • Systems Biology
  • Therapy
  • Toxicity
  • Viability

Fields of Study

  • Medicine

Readers

  • Materials Science and Engineering.
  • Molecular and Cellular Biology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.